Volume 86 Issue 8 | p. 18 | Concentrates
Issue Date: February 25, 2008

Pfizer Will Acquire Biotech Encysive

Department: Business

Pfizer has agreed to acquire Encysive Pharmaceuticals, a publicly held biopharmaceutical company whose product for the treatment of pulmonary arterial hypertension (PAH) was approved in Europe but has failed to clear U.S. regulators. Pfizer will pay about $195 million for the Houston-based company. Upon completion of the deal, it plans to conduct a Phase III clinical trial to support approval in the U.S. Pfizer already markets Revatio, a PAH treatment discovered in its own labs.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment